Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerHeikki Joensuu, Jorma Isola, Seija Ingalsuo et al.|New England Journal of Medicine|2006Cited by 1.4k
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer TrialHeikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono et al.|Journal of Clinical Oncology|2009Cited by 459
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort studyHarri Sihto, Heikki Joensuu, Johan Lundin et al.|Breast Cancer Research|2011Cited by 228
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.Heikki Joensuu, Johan Lundin, Jorma Isola et al.|PubMed|2003Cited by 209
Risk for Distant Recurrence of Breast Cancer Detected by Mammography Screening or Other MethodsHeikki Joensuu, Johan Lundin, Kaija Holli et al.|JAMA|2004Cited by 191